ProQR will deliver a short talk (ePoster) and a poster presentation on eluforsen during the ECFS:
|Abstract title:||Exploratory immune assays distinguish healthy volunteer from CF patient cohorts and were validated in a dose escalation study of QR-010 in subjects with cystic fibrosis homozygous for the F508del CFTR mutation|
|Presenter:||Miriam Bujny, Ph.D., director biomarkers of ProQR|
|Poster Presentation:||Friday, June 9 14:00 – 15:00 CET|
|ePoster Presentation:||Session: New treatments: from genes to protein. Thursday, June 7, 14:00-15:00 CET|
Presentation at 2018
ProQR’s scientific advisory board (SAB) member, Prof.
|Presentation title:||Suppression of nonsense mutations in the CFTR gene by targeted RNA pseudouridylation|
|Presenter:||Yi-Tao Yu, Prof. University of Rochester Medical Center|
|Session:||Session 2: Approaches for Targeting Nonsense Mutations|
|Schedule:||Tuesday, June 19 10:55 – 11:20 MT|
Eluforsen, formerly known as QR-010, is a first-in-class RNA-based oligonucleotide designed to address the underlying cause of the disease by targeting the mRNA in CF patients that have the F508del mutation. The technology was exclusively licensed from
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such statements include those relating to our participation at the
Chief Financial Officer
T: +1 415 231 6431
Source: ProQR Therapeutics N.V.